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Zerumbone is a natural compound isolated from the fresh rhizomes of Zingiber zerumbet. This 
bioactive compound has shown a chemo-preventive, anti-inflammatory and free radical scavenging 
activities. This study examines the effect of zerumbone on the extent of tissue damage in cisplatin-
induced nephrotoxicity in rats. The rats received a single dose injection of 10 mg/kg cisplatin. Other 
groups of rats received zerumbone (100 and 200 mg/kg), corn oil or the vehicle, dimethyl sulfoxide 
(DMSO) intraperitoneally for 4 days prior to cisplatin-injections. All animals were decapitated 16 h after 
cisplatin injection. Trunk blood was collected and analyzed for blood urea nitrogen (BUN) and serum 
creatinine. Kidney tissue was kept for the quantification of malondialdehyde and glutathione levels. 
Histopathological investigations were carried out and the severity of lesions was scored to obtain 
quantitative data. Our study revealed that zerumbone reduced kidney damage and preserved renal 
functions as proved by microscopic observations and lesion scoring. The increased in kidney 
malondialdehyde (MDA) levels with simultaneous glutathione (GSH) reduction in cisplatin treated group 
was attenuated by zerumbone (p < 0.05). It was concluded that zerumbone is beneficial in cisplatin-
induced renal dysfunction and organ damage in rats possibly via the prevention of lipid per oxidation 
and preservation of antioxidant glutathione.  
 





Cisplatin (cis-diamine-dichloroplatinum) is a prominent 
member of the effective broad-spectrum antitumour 
drugs. However, its clinical usage is restricted due to 
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ototoxicity (Ekborn et al., 2003; Iraz et al., 2005; Yao et 
al., 2007). Continued aggressive high-dose cisplatin 
chemotherapy necessitates investigating newer measures 
of preventing dose-limiting side effects that inhibit the 
administration of cisplatin at tumouricidal doses. Up till 
now, a large number of studies have been focused on 
measures of preventing cisplatin’s side effects via the 
simultaneous supplementation of preventive agents (Ali 
et al., 2006). Findings of these studies suggested that the 
side effects of cisplatin could well be protected using 
drugs and micronutrients with different chemical entity 
(Blakley et al., 2001; Leitao and Blakley, 2003; Fetoni et 
al., 2004; Kalkanis et al., 2004; Weijl et al., 2004; Kim et 





side effects are not clearly understood, it was considered 
to be attributed by various factors (Hong et al., 2005; 
Ramesh and Reeves, 2002; Nowak, 2002; Townsend 
and Hanigan, 2002; Xiao et al., 2003), amongst them 
included the generation of reactive oxygen species 
(ROS) that could interfere with the antioxidant defense 
system, resulting in oxidative damage at different tissues 
(Koc et al., 2005; Mansour et al., 2006; Iraz et al., 2006) 
and the reaction with thiols in protein and glutathione, 
which causes cell dysfunction. On the other hand, it has 
been proposed that the antitumour activity of cisplatin is 
due to its ability to form adducts with DNA, which could 
cause cross-linking of DNA strands (Kasparkova et al., 
2004). As the anti-tumour activity and side effects in 
cisplatin-based chemo-therapy are mediated in part by 
different mechanisms, the actions on selective inhibition 
of certain side effects could be achieved whilst retaining 
the antitumor activity (Leonetti et al., 2003). Furthermore, 
since the side effects in cisplatin-based chemotherapy 
were considered to be induced through various factors, a 
possible potential protective action on these side effects 
could be achieved via the combined use of preventive 
agents with different chemical entity; however, until to this 
present day, very little is known regarding the combined 
use of cisplatin with these agents. In this present 
investigation, we attempted to explore the use of these 
agents in preventing cisplatin nephrotoxicity. In regard to 
this, a natural compound belonging to a ginger plant 
family, Zingiberaceae was used. Several dietary ingredients of 
this ginger family have been known and their biological 
activities elucidated (Aggarwal and Shishodia, 2006; 
Surh, 1999). The natural compound zerumbone (ZER) 
used in our study was isolated and purified from Zingiber 
zerumbet of the ginger family. This compound is used 
initially as an anti-inflammatory adjuvant for sprain and in 
treating human ailments such as stomach ache and 
fever. In addition, its rhizome has been used frequently 
as spice in traditional cooking (Chiu and Chang, 1986).  
Several reports on the bioactivities of ZER have been 
reported, which included anticarcinogenesis (Takada et 
al., 2005), anti-inflammation (Murakami et al., 2003) and 
most recently from our own laboratory, ZER’s anticancer 
effect on cervical tissues (Abdul et al., 2008). Besides, 
ZER was also found to act synergistically as an anticancer 
agent during experimental cervical intraepithelial neoplasia 
in mice. In this present study, we investigated the preventive 
effect of zerumbone on cisplatin-induced nephrotoxicity 
using microscopy examination of rat kidney tissues after 
H and E (hematoxylin and eosin) staining and further 
evaluating blood kidney enzymes functions and levels of 
malondialdehyde (MDA), the end product of lipid peroxidation 
in kidney tissues, as biomarkers. 
 
 
MATERIALS AND METHODS 
 
Reagents and laboratory wares 
 
All reagents used in this study are of  analytical  grade.  All  glasses 




and plastic wares were washed with detergent and acid, and rinsed 
several times with distilled water. Cisplatin and the other chemicals 
were obtained from Sigma Chemical Co., St. Louis, MO, USA. 
 
 
Isolation and characterization of ZER 
 
ZER was isolated using the hydrodistillation (steam distillation) 
method. Briefly, fresh rhizomes of Z. zerumbet were initially cleaned 
and sliced and later placed in a glass flask containing distilled water 
and heated immediately using the heating mantel. The flask was 
immediately connected to special glassware (Dienstag) in order to 
collect vaporized steam containing the volatile oil. Then volatile oil 
was crystallized using circulating cool water. The crystals were 
collected and used. To obtain highly pure ZER, recrystalization was 
performed using hexane and the solution was left standing to 
evaporate. Thin layer chromatography was used to examine 
purification of ZER at each step. The crystals of ZER were kept for 
further chemical and pharmacological analyses. 
 
 
ZER structure elucidation by nuclear magnetic resonance 
(NMR)  
 
Five milligrams of ZER crystals were dissolved in high performance 
liquid chromatography (HPLC)-grade methanol and the sample was 
subsequently sent for NMR analysis at the laboratory of Natural 
Products, Institute of Bioscience, University Putra Malaysia (UPM). 
1Hydrogen and 13Carbon NMR spectra were recorded in Varian 
Unity Inova spectrometer operated at 500 MHz and the chemical 





Thirty five (35) female rats (Sprague-Dawley) of 150 - 200 g weight, 
procured from the Animal House Unit, Faculty of Veterinary 
Medicine, UPM were used. The animal room at the Institute 
Bioscience, UPM was maintained at a temperature of 25 ± 2°C with 
a 12 h light/dark cycle and a relative humidity of 50 – 60%. Free 
access to food and water was allowed at all times. Rats were 
housed five per cage in sterilized plastic cages using homogenized 
wood shavings as bedding. All experimental protocols held on 
animals were done according to regulations set by the Institutional 






The rats were divided into groups (n = 5): Rats in Group 1 were 
intraperitoneally pretreated for 4 days with ZER (100 mg/kg per day, 
in corn oil). Rats in Group 2 were intraperitoneally pretreated for 4 
days with ZER (200 mg/kg per day, in corn oil). Three hours after 
ZER pretreatment, a dose of 10 mg/kg of cisplatin was injected into 
rats in Groups 1 and 2. Rats in Group 3 were intraperitoneally 
treated by cisplatin as positive control. Group 4 were intraperitoneally 
treated with corn oil. Rats in Group 5 were intraperitoneally treated 
with ZER (100 mg /kg) as a control for Group 1. Rats in Group 6 
were intraperitoneally treated with ZER (200 mg/kg) as a control for 
Group 2. Rats in Group 7 were intraperitoneally treated with 
dimethyl sulfoxide (DMSO) in distilled water, as a control for the 
cisplatin group. All animals were injected in similar volume 
injections. Since higher doses of cisplatin showed evidence of 
tissue damage between 8-15h after injection (Liu et al., 1998), the 
rats were killed under ether anesthesia; 16 h after injection and 
blood, kidney tissues were then collected. Trunk blood was 
collected and  analyzed   for   serum   creatinine   and   blood   urea  




Table 1. Kidney serum enzymes of control and cisplatin treated rats and the effect of 
zerumbone pre-treatment.   
 
Groups CREAT (mg/dl) BUN (mg/dl) 
Mean SD Mean SD 
100 ZER + CIS 91.25 16.42 7.53 2.29 
200 ZER + CIS 73.00 12.17 7.95 3.51 
Cisplatin 123.67* 16.77 17.30* 0.61 
Corn Oil Negative Control  70.50 4.20 6.83 0.68 
DMSO control 75.50 8.89 7.33 1.27 
200 ZER 72. 00 4.42 7.62 0.72 
100 ZER 77. 00 7.00 5.33 1.25 
 
CREAT: Creatinine; BUN: blood urea nitrogen.  Data are means ± SD of five rats for each 




nitrogen (BUN). After bleeding, kidney samples were removed and 
fixed in 10% formaldehyde for histopathological examinations or 
stored at −80°C for subsequent measurement of malondialdehyde 
(MDA) and glutathione (GSH) levels. 
 
 
Determination of kidney functions 
 
As indicators of kidney function, serum creatinine and BUN levels 
were measured. All biochemical assays were performed spectro-
photometrically using Hitachi-912 Autoanalyser (Mannheim, Germany) 
with kits supplied by Roche Diagnostics (Mannheim, Germany). To 
obtain data with good sensitivity and validity, serum samples were 
analyzed in triplicates and blindly analyzed. 
 
 
Histopathological examinations  
 
Animal tissue was fixed in 10% formalin. Kidney samples embedded in 
parafin and sectioned at 5 µm were stained with hematoxylin-eosin. 
All sections were examined using a photomicroscope (Olympus BH-
2, Japan). At least five microscopic areas were examined to score a 
specimen. The renal injury was based on degeneration of Bowman 
space and glomeruli, degeneration of proximal and distal tubuli, 
vascular congestion and interstitial edema. Each specimen was 
score using a scale ranging from 0 to 3 (0: none, 1: mild, 2: 
moderate and 3: severe) for each criterion. The total score was 9 
for kidney. Histological examination and scoring were performed by 
an observer (F.E.) unaware of the treatment groups. 
 
 
Measurement of tissue MDA 
 
Levels of MDA were assayed by the method of Satoh. Briefly, 10% 
(weight/volume) homogenate of kidney made by 0.1 mol/L 
phosphate buffer was centrifuged at 4°C; 3500 rpm for 10 min. 0.2 
mL supernatant was mixed with 0.67% 2-thiobarbituric acid (TBA) 
and 20% trichloroacetic acid solution and heated in a boiling water 
bath for 30 min. The pink-colored chromogen formed by the reaction of 
TBA with MDA was measured at 532 nm. The results were expressed 
as MDA nmol/mg protein. Contents of protein in the supernatant 
were measured by Lowry’s method (Yingjun et al., 2008). 
 
 
Measurement of tissue GSH levels 
 
The tissue samples were homogenized in 10 volumes of ice-cold 
10% trichloroacetic  acid  and  centrifuged  at  1000 g  for 15 min  at 
4°C. Supernatant was removed and recentrifuged at 35,000 g at 
4°C for 8 min. GSH was determined using a spectrophotometric 






All data are expressed as mean ± SD. Histological data (Lesion 
Scoring) were compared using Kruskal- Wallis non-parametric test 
whilst other parameters were compared by one-way ANOVA 
followed by post hoc Tukey’s honestly significant difference (HSD) 
multiple comparison tests. The type 1 error level was set at p < 0.05 
for all tests. All statistical analyses were performed using statistical 
package for the social sciences (SPSS) software (Chicago, IL, 





The effect of zerumbone on cisplatin-induced kidney 
dysfunction 
 
The results of this study showed that cisplatin caused a 
significant reduction in renal function, as characterized by 
remarkable increased in serum creatinine and BUN levels 
(Table 1). These findings indicate strongly that the single 
intra-peritoneal injection of 10 mg/kg cisplatin harms 
renal function. 
Pretreatment with zerumbone for 4 days significantly 
overturned cisplatin-induced elevation in serum creatinine 
and BUN levels. Treatment with DMSO and corn oil 
however did not induce any abnormal changes in the 
serum level of kidney enzymes. In addition, serum levels 
of these enzymes are not affected by the treatment with 
zerumbone (Table 1). 
 
 
The effect of zerumbone on qualitative and 
quantitative histopathology and clinical observation 
 
No death was observed among all groups during the 







A-cisplatin 10 mg/kg 
A1  Severe glomerular congestion.  






B-ZER 100 mg/kg+ cisplatin 10m g/kg 
B1  Moderate glomerular congestion. 






C-ZER 200 mg/kg + cisplatin 10 mg/kg 
CI  Mild Glomerular Congestion. 
C2 Mild Tubular Degeneration in Tubular Cells. 






D-ZER 200 mg/kg control 
D1 Normal Histological Appearance of Glomeruli, 






E-ZER 100 mg/kg control 
E1 Normal Histological Appearance of Glomeruli, 




observed under microscopy. Kidney tissues in cisplatin- 
administered animals showed cellular damage. Renal 
damage was recognized by severe degeneration in 
glomeruli and tubuli (both proximal and distal tubuli). In 
zerumbone pre-treated animals, the morphology of renal 
tissue is near normal. The morphological feature of 
kidney tissues from zerumbone injected animals is similar 
to the control morphology, which revealed normal and 
regular appearance of both glomeruli and tubuli (Figure 1: 
A - G). With reference to the morphological appearance 
of kidney tissues from cisplatin injected animals, their 
quantitative lesions scoring mean is statistically higher 
than that of normal control group (p < 0.05). Zerumbone 
administration reduced the microscopic lesion scoring 
effectively (p < 0.05) (Table 1).  
Total mean scoring, degeneration of Bowman space 
and glomeruli, degeneration of proximal and distal  tubuli,  






F-Negative control CORN OIL 
F1 Normal Histological Appearance of Glomeruli, 





vascular congestion and interstitial edema was used as 
indices to evaluate the lesions quantitatively as earlier 
mentioned. In respect to these indices, the highest mean 




The effect of zerumbone on MDA and GSH levels 
 
Lipid peroxidation in kidney tissues was evaluated using 
measurements of MDA levels quantitively. In cisplatin 
injected animals, MDA level was markedly higher compared 
to normal control. Pretreatment with zerumbone decreases 
the levels of MDA which are significantly different from 
the mean of MDA in cisplatin treated animals (Table 3). 
Meanwhile, the indigenous level of GSH was strongly 
depleted by a single intraperitoneal injection of 10 mg/kg 
cispaltin. However, this depletion has been reversed by 
prior treatment of zerumbone at 100 and 200 mg/kg 





Platinating agents are an important class of chemotherapeutic 
agents, with cisplatin and carboplatin used in treating 
testicular, gynecologic, head and neck and lung 
carcinomas (Rabik and Dolan, 2007). Contraindications 
of cisplatin are documented as the important dose-
limiting factor in cancer chemotherapy, but at high doses 
of cisplatin, hepatotoxicity as well as nephrotoxicity does 
transpire (Weijl et al., 2004). Hence, to overcome such 
contraindications, the potential use of natural products of 
plant origin has been examined (Hong et al., 2005).  







G-Nagative control DMSO 
G1 Normal Histological Appearance of Glomeruli, 
G2 Semi Normal Histological Appearance of Tubular Cells. 
 
Figure 1. Photomicrographs of kidney samples of the control, 
cisplatin, or 100 and 200 mg kg-1 ZER-treated cisplatin 
groups. Control group (G), (F): normal histological 
appearance of kidney. Cisplatin group (A): severe 
glomerular congestion   and degeneration, dilatation in 
Bowman’s space, and degeneration in tubular cells   in kidney 
.Cisplatin + 200 mg ZER group (C): Mild glomerular and 
tubular degeneration in kidney. Cisplatin + 100 mg ZER 
group (C) Normal Histological appearance of Glomeruli and 
Normal Histological appearance of Tubular Cells.  
Hematoxylin–eosin staining, original magnifications: ×400. A: 
10 mg/kg cisplatin; B: 100 mg/kg ZER + 10 mg/kg cisplatin; C: 
200 mg/kg ZER + 10 mg/kg cisplatin; D: 200 mg/kg ZER + 10 
mg/kg cisplatin; E: 100 mg/kg ZER + 10 mg/kg cisplatin; F: 




potential nephro-protective compounds such as curcumin 
and xanthorrhizol (Kim et al., 2005). Zerumbone, a phyto-
chemical isolated from Z. zerumbet of the Zingiberaceae 
family, has shown to possess chemopreventive, free 
radical scavenging activities and activating properties 
towards phase II drug metabolizing enzymes (Murakami 
et al., 2003; Abdul et al., 2009). In addition, the cytotoxic 
property of zerumbone was known to be cytoselective 
towards cancer cells compared to normal cells (Sakinah 
et al., 2007).  
Our previous study demonstrated that zerumbone acts 
synergistically with cisplatin to inhibit cervical intra-
epithelial neoplasia induced in female Balb/c mice. This 
synergism led to the lowering of the curative dose of 
cisplatin and subsequently to its clinical complications 
(Abdul et al., 2008). 
Experiments in animals have shown that a minimum 
dose of cisplatin (5 mg/kg body weight) was adequate to 
persuade toxicity in rats (Ravi et al., 1995). A higher dose 
of cisplatin (12 mg/kg weight) corresponds to the 
equivalent human dose presently being used. In this 
study, a dose of cisplatin (10 mg/kg body weight, i.p.) was 
used   that  demonstrated  significant  increase  in  kidney  




Table 2.  Lesions scoring of the control, cisplatin or cisplatin + ZER. 
 
Treatment Degeneration of Bowman 
space and glomeruli 
Degeneration of proximal 
and distal tubuli 
Vascular congestion and 
interstitial edema 
Mean SD Mean SD Mean SD 
100ZER+Cisplatin 1.33 0.44 1.00 0.28 0.33 0.00 
200ZER+Cisplatin 0.80 0.25 1.60 0.51 0.24 0.21 
CISPLATINPLATIN 3.00* 0.00 3.00* 0.00 3.50* 1.50 
Corn Oil Negative control  0.00 0.00 0.00 0.00 0.00 0.00 
DMSO Control 0.00 0.00 0.00 0.00 0.00 0.0 
200ZER 1.25 0.40 1.75 0.50 0.50 0.12 




Table 3. The tissue malondialdehyde (MDA) level, glutathione (GSH) content of the control, cisplatin-
injected and zerumbone pretreated groups.  
 
Treatments MDA (nmol/g) GSH (µmol/g) 
Mean SD Mean SD 
ZER100+Cisplatin 0.38 0.05 1.66 0.15 
ZER200+Cisplatin 0.33 0.10 1.90 0.16 
Cisplatin 1.10* 0.17 4.87* 0.36 
Corn Oil Negative Control 0.41 0.09 1.91 0.14 
DMSO 0.43 0.07 1.89 0.12 
200ZER 0.40 0.12 1.73 0.11 
100ZER 0.42 0.11 1.70 0.11 
 
Data are means ± SD of five rats for each group.  




serum enzymes, MDA and GSH as well as in causing 
histopathological lesions in kidney compared to normal 
control groups. 
Biochemical evidence of renal injury has been demon-
strated by elevated levels of BUN and serum creatinine. 
In our present study, intraperitoneally administrated cisplatin 
(10 mg/kg) led to elevated levels of these biochemical 
markers. In contrast, intraperitoneal pretreatment with 
zerumbone (100 and 200 mg/kg) significantly abrogated 
these elevations. These biochemical findings were 
confirmed by evidences of microscopic examinations. 
Platinating agents become aquated in cellular cytoplasm, 
which enables them to react with thiol containing 
molecules, including GSH. Increased concentrations of 
these compounds are known to induce resistance against 
cisplatin (Ali et al., 2006). Glutathione acts as an 
antioxidant to the cell; it helps to maintain the redox 
environment while maintaining the reduced sulfhydryl 
groups. Cisplatin is thought to be detoxified by glutathione 
through an adduct formation (Ali et al., 2006; Hoffman et 
al., 2002). 
In agreement to the above, this study revealed elevations 
in renal glutathione levels in rats treated with zerumbone 
as compared to the control, DMSO and corn oil groups. 
Glutathione uptake is one of the mechanisms of cells to 
sustain intracellular thiol redox status (Visarus et al., 
1996). Thus, it is possible to speculate that a positive 
regulation in the biosynthesis of glutathione may contribute 
to an increase in its intracellular contents. In this context, 
we postulated that zerumbone indirectly induces the 
biosynthesis of glutathione and provided a protective intra-
cellular mechanism, presumably as free radical scavenger 
for toxic agents. Hoffman et al. (2000) had proposed a 
redox model of cell proliferation and suggested an appro-
priate dose of zerumbone that will enhance intracellular 
redox potential (E) in cancer cells. In this aspect, 
zerumbone is thought to deplete intracellular reduced 
glutathione, thereby raising E, which in turn stops the 
proliferation of the cancer cells. On the other hand, 
normal cells partially increased the redox potential E. In 
relation to this, our study indicates enhanced levels of 
antioxidant glutathione (reduced form) in non-cancerous 
rat kidney tissues after pretreatment with zerumbone. We 
find these results interesting since pretreatment using 
appropriate dose of zerumbone is able to reduce cisplatin 
nephrotoxicity in noncancerous rats; in tandem with 
zerumbone is reported to be a potential anti-cancer agent 
(Abdul et al., 2008; Sakinah et al., 2007). This could 
mean that zerumbone is specific towards cancer cells but 
causing less adversity towards normal surrounding tissues,  




concurrently to previous findings from our laboratory 
(Abdul et al., 2008). 
Previous data have mentioned that cisplatin induces 
oxidative stress and lipid peroxidation, whereby cisplatin 
induced nephrotoxicity is narrowly related to an increase 
in lipid peroxidation in kidney tissues (Yüce et al., 2007). 
In our present study using laboratory rats, renal injury 
develops after intraperitoneally injecting high dose of 
cisplatin (10 mg/kg), whilst renal toxicity became obvious 
as early as 8 h after injection, as indicated by marked 
elevations in the kidney biomarker enzymes and MDA 
levels in rats’ kidney tissues. 
Many natural products have been evaluated as potential 
chemopreventive agents (Hong et al., 2005). The effects 
of pretreatment of a natural antioxidant on cisplatin-induced 
renal damages have been previously investigated and 
reported elsewhere (Hong et al., 2005; Ali et al., 2006). 
The findings of this study however have demonstrated in 
vivo that pretreatment with a natural compound such as 
zerumbone prevented kidney cells from further tissue 
damages as evidenced by the significant difference bet-





It can be concluded that cisplatin, when administrated at 
a dose of 10 mg/kg, induced renal damages as evidenced 
by the qualitative and quantitative histopathology and 
biochemical analysis. DMSO and corn oil did not induce 
any crossing effect, which clearly shows the validity of the 
experimental design of this study. On the other hand, 
zerumbone pretreatment was beneficial in cisplatin-induced 
renal dysfunction and organ damage in rats, presumably 
via the prevention of lipid peroxidation and preservation 
of antioxidant glutathione. Therefore, these beneficial 
effects could be responsible for providing nephro-protective 
properties and hence, anti-cancer chemopreventive 
potential. It is therefore, strongly recommended to consider 
this natural compound to be a useful co-treatment for 
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